Bio-XL Ltd
Pharmaceuticals - Yavne, Center District, Israel
Bio-XL Ltd Employees
Bio-XL Ltd Details
Bio-XL selects innovative pharma technologies and facilitates their development into new pharmaceutical drugs and treatments.*We actively invent, scout, develop and in-license innovative technologies that can be transformed into new drugs or treatments:a. Target large patient populations with significant unmet needsb. Develop a balanced and diverse pipeline of bio/pharmaceutical drugs in various medical areasc. Maintain contacts and engagement with pharma companies, in the relevant areas, from early development stagesd. Focused product development to clinical stage and registratione. Leveraging funds by working with lean operations teamOperation principles:*Bio-XL prepares each technology to become a new independent company, by:a. Evaluation of technology; preparation of development & financial plansProvision of initial financeb. Carry out discovery-R&D studies to demonstrate PoCc. Fund raising and establishment of independent NewCod. "Nurturing" NewCo until reaching full independence*The criteria for establishment of a NewCo:a. Demonstration of PoCb. Reaching preclinical stagec. Fund raising*Fund raised per NewCo should be sufficient to reach high valuation point (e.g "EXIT point"): IPO, acquisition or engagement of a strategic partner Current portfolio of Bio-XL includes technologies at different development stages:*"Klothix-Therapy": Cancer therapy for PDAC and TNBC (pre-clinical)*"Klothix-Diagnostic": Detection test for early diagnosis (pre-clinical)*"AMP-Bio": Novel antibiotics for multi-drug resistant pathogens (discovery)*"NES-Pharma": New Approach for Delaying Symptoms of Age-related Cognitive Disorders (e.g. Alzheimer Disease) (Discovery)*"Marathon": Delivery of mitochondria in Mitochondrial Replacement Therapy (Discovery)*"COV-ex": Targeting ACE2 receptor to slow down COVID-19 virus infection
